Rapamycin for dogs with cancer

help your dog live longer.

Buy Rapamycin now.

Rapamycin for dogs with cancer

Rapamycin for Dogs with Cancer

Rapamycin is commonly used to fight cancer in humans, and there are a number of ongoing clinical trials studying the use of rapamycin for dogs with cancer.

Rapamycin targets mTOR, an important regulator of cell division and tumor blood supply.  By inhibiting mTOR, rapamycin can in theory reduce tumor growth, tumor nourishment, and tumor spread via new blood vessels.  Learn more about how rapamycin works here.

Here’s a summary of using  rapamycin for dogs with cancer….

Rapamycin for Dogs with Lymphoma

Study 1:  the pAKT/mTOR pathway is present only in malignant, but not normal, lymphoblasts.  A novel pAKT/mTOR inhibitor produced dose-dependent inhibition of malignant cell proliferation

Study 2: Low dose rapamycin inhibited lymphoma cell proliferation, while high dose rapamycin actively killed lymphoma cells.

Study 3: Aberrant mTOR regulation plays a role in many blood cancers, and thus mTOR inhibitors like rapamycin should be routinely considered in their management.

 

 

Rapamycin for dogs with lymphoma
Rapamycin for dogs with hemangiosarcoma

Rapamycin for Dogs with Hemangiosarcoma

Study 1: Low dose rapamycin inhibited HSA cell proliferation, while high dose rapamycin actively killed HSA cells.

Study 2: Inhibitors of the pI3K/AKT/mTOR pathways reduce the proliferation of canine HSA cells.

Study 3: In vitro effects of rapamycin on canine HSA cells

Clinical Trial on rapamycin and canine HSA

 

Rapamycin for Dogs with Osteosarcoma

Study 1:  mTOR is a primary driver for osteosarcoma cell multiplication, so inhibiting mTOR with rapamycin may reduce tumor enlargement.

Study 2: Rapamycin did not alter the course of canine osteosarcoma

Clinical Trial on rapamycin for the adjunctive treatment of canine osteosarcoma

rapamycin for dogs with osteosarcoma
rapamycin for dogs with melanoma

Rapamycin for Dogs with Melanoma

Study 1:  mTOR is present and active in multiplying melanoma cells.  Rapamycin, through its mTOR inhibition, will inhibit melanoma cell proliferation and tumor growth.

Study 2: mTOR is present and active in melanoma skin tumors, and thus rapamycin and other mTOR inhibitors may be a logical intervention.

Study 3: mTOR inhibitors are synergistic with carboplatin in the treatment of canine melanoma

 

Rapamycin for Dogs with Mammary Cancer

Study 1: Low dose rapamycin inhibited mammary cancer cell proliferation, while high dose rapamycin actively killed mammary cancer cells.

Study 2: activated mTOR was not found in normal dog mammary tissue, but was present in 78% of canine mammary tumors.

Study 3: Overview of mTOR inhibition for breast cancer

rapamycin for dogs with mammary cancer
rapamycin for dogs with mast cell tumors

Rapamycin for Dogs with Mast Cell Tumors

Study 1: Low dose rapamycin inhibited mast cell proliferation, while high dose rapamycin actively killed mast cells.

Study 2: mTOR plays a large role in the abnormal function of mast cells.

Need help with your dog’s journey through cancer?

RAPAMYCIN FOR DOGS

KEVIN TOMAN, dvm

ktomandvm@gmail.com

625 Pacific Ave, Cayucos CA 93430